Grundläggande statistik
| CIK | 1328003 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Redpoint Bio Corp.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| April 21, 2015 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 15, 2015 REDPOINT BIO CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51708 22-3393959 (State of Incorporation) (Commission File No.) (IRS Employe |
|
| August 4, 2014 |
Exhibit 16.1 August 1, 2014 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We were previously principal accountants for Redpoint Bio Corporation and, under the date of April 16, 2012, we reported on the financial statements of Redpoint Bio Corporation as of December 31, 2011 and 2010, and for each of the years in the three-year period ended December 31, 2011 and fo |
|
| August 4, 2014 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 1, 2014 REDPOINT BIO CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51708 22-3393959 (State of Incorporation) (Commission File No.) (IRS Employe |
|
| January 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 10, 2014 REDPOINT BIO CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51708 22-3393959 (State of Incorporation) (Commission File No.) (IRS Emplo |
|
| December 5, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 2, 2013 REDPOINT BIO CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51708 22-3393959 (State of Incorporation) (Commission File No.) (IRS Emplo |
|
| July 2, 2013 |
8-K 1 v3492388k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 2, 2013 REDPOINT BIO CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51708 22-3393959 (State of Incorporation) (Commis |
|
| May 30, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 23, 2013 REDPOINT BIO CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51708 22-3393959 (State of Incorporation) (Commission File No.) (IRS Employer |
|
| May 30, 2013 |
TRANSFER AGREEMENT AND BILL OF SALE EXHIBIT 10.1 TRANSFER AGREEMENT AND BILL OF SALE THIS TRANSFER AGREEMENT AND BILL OF SALE (this “Agreement”) is entered into as of May 23, 2013 by and between Janssen Pharmaceuticals, Inc., a Pennsylvania corporation having its principal place of business at 1125 Trenton-Harbourton Road, Titusville, NJ 08560 (“Buyer”), and Redpoint Bio Corporation, a Delaware corporation having its principal place |
|
| September 10, 2012 |
Quarterly Report - FORM 10-Q/A United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51708 Redpoin |
|
| August 20, 2012 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51708 Redpoint |
|
| August 20, 2012 |
EXCHANGE TRANSACTION AGREEMENT EXCHANGE TRANSACTION AGREEMENT This EXCHANGE TRANSACTION AGREEMENT (this “Agreement”) is made and entered into as of June 14, 2012, by and between Redpoint Bio Corporation, a Delaware corporation (“Redpoint”), and Celator Pharmaceuticals, Inc. |
|
| August 20, 2012 |
TERMINATION AGREEMENT THIS AGREEMENT (this “Agreement”) is dated as of August 10, 2012, by and between Redpoint Bio Corporation, a Delaware corporation (“Redpoint”), and Celator Pharmaceuticals, Inc. |
|
| August 15, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: June 30, 2012 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Form N-SAR For the Transition Period Ended: Read Instruction (on back page) Before Preparing Form. |
|
| August 13, 2012 |
Termination of a Material Definitive Agreement 8-K 1 v3211988k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 10, 2012 REDPOINT BIO CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51708 22-3393959 (State of Incorporation) (Commissi |
|
| June 18, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 12, 2012 REDPOINT BIO CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51708 22-3393959 (State of Incorporation) (Commission File No.) (IRS Employer |
|
| June 18, 2012 |
EX-10.1 2 v316087ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Redpoint Bio Corporation 5501 Old York Road Philadelphia, Pennsylvania 19141 June 12, 2012 Mr. Scott Horvitz 7 Timber Knoll Drive Washington Crossing, PA 18977 Re: Employment Compensation Dear Mr. Horvitz: As you know, on September 27, 2011, the Board of Directors (the “Board”) of Redpoint Bio Corporation (the “Company”), and you agreed, due to |
|
| June 18, 2012 |
Exhibit 10.2 Redpoint Bio Corporation 5501 Old York Road Philadelphia, Pennsylvania 19141 June 12, 2012 Dr. F. Raymond Salemme 1970 Timber Lakes Drive Yardley, PA 19067 Re: Employment Compensation Dear Dr. Salemme: As you know, on September 27, 2011, the Board of Directors (the “Board”) of Redpoint Bio Corporation (the “Company”), and you agreed, due to the financial condition of the Company, to r |
|
| May 21, 2012 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51708 Redpoint |
|
| May 16, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: March 31, 2012 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Form N-SAR For the Transition Period Ended: Read Instruction (on back page) Before Preparing Form. |
|
| April 16, 2012 |
ASSET PURCHASE AGREEMENT THIS ASSET PURCHASE AGREEMENT (“Agreement”) is made effective September 30, 2011, by and between REDPOINT BIO CORPORATION, a Delaware corporation with its principal executive offices at 7 Graphics Drive, Ewing, New Jersey 08628 (“Seller”), and OPERTECH BIO, INC. |
|
| April 16, 2012 |
Exhibit 21.1 List of Subsidiaries None. |
|
| April 16, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-51708 REDPOINT BIO CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 22-3393959 (I. |
|
| April 2, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2011 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Form N-SAR For the Transition Period Ended: Read Instruction (on back page) Before Preparing Form. |
|
| January 26, 2012 |
EXHIBIT 17.1 January 20, 2012 Board of Directors Redpoint Bio Corporation 5501 Old York Road Philadelphia, PA 19141 Ladies and Gentlemen: Effective as of January 31, 2012, please accept my resignation as a director of Redpoint Bio Corporation (the “Company”). There is no disagreement between the Company and me on any matter relating to the Company’s operations, policies or practices. Very truly yo |
|
| January 26, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 20, 2012 REDPOINT BIO CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-51708 22-3393959 (State of Incorporation) (Commission File No.) (IRS Emplo |
